Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality... Show more
MDGL's Aroon Indicator triggered a bullish signal on September 05, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator showed a similar pattern. In of the 161 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The 50-day moving average for MDGL moved above the 200-day moving average on August 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.812) is normal, around the industry mean (20.107). P/E Ratio (0.000) is within average values for comparable stocks, (52.767). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.138). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (18.382) is also within normal values, averaging (327.388).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
CGFEX | 83.01 | 0.20 | +0.24% |
American Funds Growth Fund of Amer 529E | |||
JOEAX | 13.90 | N/A | N/A |
JOHCM Emerging Markets Opps Investor | |||
DRESX | 25.19 | N/A | N/A |
Driehaus Emerging Markets Small Cap Gr | |||
GFCUX | 24.30 | N/A | N/A |
Goldman Sachs Enhanced U.S. Equity R6 | |||
LAMSX | 24.83 | N/A | N/A |
Lord Abbett Dividend Growth R4 |
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.
Ticker / NAME | Correlation To MDGL | 1D Price Change % | ||
---|---|---|---|---|
MDGL | 100% | +0.39% | ||
ALXO - MDGL | 56% Loosely correlated | +12.96% | ||
NAGE - MDGL | 45% Loosely correlated | +0.97% | ||
IPHA - MDGL | 44% Loosely correlated | -2.20% | ||
RNAC - MDGL | 43% Loosely correlated | +6.40% | ||
GHRS - MDGL | 43% Loosely correlated | +0.28% | ||
More |